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Latar Belakang: Kanser payudara adalah merupakan kanser yang paling biasa 
menyerangi kaum wanita dan kadar insiden semakin meningkat setiap tahun di seluruh 
dunia. Tamoksifen ialah ubat kemoterapeutik utama digunakan dalam merawat pesakit 
kanser payudara. Walaubagaimanapun, komplikasi ginekologi dan rintangan terhadap 
ubat merupakan antara kesan buruk yang utama terutamanya selepas 10-15 tahun rawatan 
dengan tamoksifen. Kemudian, kemungkinan berlakunya perulangan kanser payudara 
yang juga boleh menyumbang kepada penyebab utama kepada kematian yang berpunca 
daripada kanser tersebut. Garcinia hombroniana (GH) (manggis hutan) ialah sejenis 
pokok yang telah dilaporkan mempunyai kesan sitotoksik yang baik dalam melawan 
pertumbuhan pelbagai jenis sel titisan kanser, termasuklah MCF-7. Oleh sebab itu, tujuan 
kajian ini adalah untuk melanjutkan penyiasatan kesan-kesan anti-proliferasi dan 
apoptosis minyak pati yang telah diekstrak daripada daun GH terhadap dua jenis sel titisan 
kanser payudara yang berbeza, iaitu MCF-7 dan MCF-7/TAMR-1. 
Kaedah: Minyak pati telah diekstrak daripada daun GH melalui proses 
penghidrosulingan. Kesan anti-proliferasi minyak pati terhadap sel-sel titisan MCF-7 dan 
MCF-7/TAMR-1 ditentukan menggunakan asai MTT dan dinilai melalui pembaca plat 
mikro. Mekanisme kematian sel ditentukan menggunakan asai pewarna Aneksin V-
FITC/propidium iodida dan diukur secara kuantitatif melalui aliran sitometri. Sel titisan 
payudara bukan kanser iaitu MCF-10A juga dinilai dalam kedua-dua asai sebagai sel 
kawalan untuk dibandingkan kepada sel MCF-7 dan MCF-7/TAMR-1.  
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Keputusan: Keputusan telah menunjukkan bahawa minyak pati GH mempamerkan kesan 
anti-proliferasi melawan pertumbuhan kedua-dua jenis sel MCF-7 dan MCF-7/TAMR-1 
yang bersandarkan kepada dos dan masa, dengan nilai IC50 masing-masing 35.22 µg/mL 
and 17.67 µg/mL. Utamanya, minyak pati GH menunjukkan kesan toksik yang rendah 
terhadap sel titisan payudara bukan kanser, MCF-10A, dengan nilai IC50 76.11 µg/mL. 
Tambahan pula, analisis aliran sitometri juga selanjutnya mengesahkan kematian yang 
diaruh oleh minyak pati GH berlaku melalui mekanisme apoptosis. 
Kesimpulan:  Kajian ini menyimpulkan bahawa minyak pati GH menunjukkan kesan 
anti-proliferasi yang kuat terhadap kedua-dua sel kanser payudara manusia iaitu MCF-7 
dan MCF-7/TAMR-1. Berdasarkan nilai IC50, MCF-7/TAMR-1 yang mewakili sel titisan 
payudara yang berfenotip rintangan terhadap tamoksifen, adalah lebih sensitif terhadap 
rawatan minyak pati GH.  Paling utama, minyak pati GH menunjukkan aktiviti sitotoksik 
yang rendah terhadap sel titisan payudara bukan kanser, MCF-10A. Keputusan-keputusan 
ini dapat menjelaskan sebahagian kepada tindakan minyak pati yang bersifat selektif 
terhadap sel-sel titisan kanser payudara tetapi tidak kepada sel normal. Di samping kesan 
sitotoksik yang selektif, tindakan perencatan minyak pati GH dalam melawan 
pertumbuhan sel-sel kanser payudara manusia MCF-7 dan MCF-7/TAMR-1 juga 
diperantarakan melalui apoptosis. Oleh itu, minyak pati GH sangat berpotensi untuk 







Background: Breast cancer is the most common cancer affected women and the incidence 
rate is increasing yearly throughout the world. Tamoxifen is the first-line 
chemotherapeutic drug used in treating breast cancer patients. However, gynaecological 
complications and drug resistance are among the major drawback effects of tamoxifen, 
particularly at 10-15 years of post-treatment. Thereafter, breast cancer recurrence may 
occur which also contribute to the major causes of breast cancer-related deaths. Garcinia 
hombroniana (GH) (seashore mangosteen) is a plant that has been reported to possess 
good cytotoxic effect against the growth of various human cancer cell lines, including the 
MCF-7. For this reason, the aim of this study was to further investigate the anti-
proliferative and apoptotic effects of the essential oil extracted from the leaves of GH 
against two different types of breast cancer cell lines, MCF-7 and MCF-7/TAMR-1.  
Methods: The essential oil was extracted by hydrodistillation process from the leaves of 
GH. The anti-proliferative effects of the essential oil against MCF-7 and MCF-7/TAMR-
1 cancer cell lines were determined using MTT assay and measured by a microplate 
reader. The mechanism of cell death was determined using Annexin V-FITC/propidium 
iodide staining assay and quantitatively measured by flow cytometry. The human non-
cancerous breast cell line, MCF-10A was also included in both assays as comparative 
control cells to the MCF-7 and MCF-7/TAMR-1 cells. 
Results: The results showed that the GH essential oil exhibited anti-proliferative effect 
against the growth of both MCF-7 and MCF-7/TAMR-1 cells following dose- and time-
dependent manners, with an IC50 of 35.22 µg/mL and 17.67 µg/mL, respectively. 
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Importantly, it exhibited low toxicity effect against the non-cancerous human breast cell 
line, MCF-10A, with an IC50 of 76.11 µg/mL. Additionally, flow cytometric analysis also 
further confirmed that the cell death induced by GH essential oil occurred via the 
mechanism of apoptosis. 
Conclusions: This study concluded that the essential oil of GH exhibited potent 
antiproliferative effects against both MCF-7 and MCF-7/TAMR-1 human breast cancer 
cells. Based on the IC50 values, the MCF-7/TAMR-1, which represents tamoxifen-
resistant phenotype breast cancer cell line, was more sensitive towards the GH essential 
oil treatment. Importantly, GH essential oil demonstrated low cytotoxicity towards the 
non-cancerous breast cell line, MCF-10A. These findings may at least in part explain to 
the selectivity of GH essential oil in killing breast cancer cell lines but not in normal 
counterpart. Besides its selective cytotoxic effect, the growth inhibitory action of GH 
essential oil against MCF-7 and MCF-7/TAMR-1 human breast cancer cells also mediated 
by apoptosis. Therefore, GH essential oil could be developed as a new, selective and 





1.1 Background of the study  
          Cancer is defined as a group of disease that is characterized by abnormal cell growth 
which tends to proliferate in an uncontrollable way and metastasize to distant sites of the 
body (National Cancer Institute, 2015). GLOBOCAN database indicated that the 
worldwide cancer morbidity has increased to more than 18 million cases and mortality has 
increased to more than 9.5 million cases in 2018 (Bray et al., 2018). Breast cancer is now 
leading cause of cancer incidence among females and it is the second most common cause 
of death after lung tumour in both males and females (GLOBOCAN, 2018). All over the 
world, both in developed and developing nations, breast cancer is becoming a major health 
problem among females. In South-Eastern countries, Malaysian women have the largest 
mortality rate of breast cancer (Nordin et al., 2018). Although chemotherapies are 
commonly prescribed for the control of breast cancer, the drugs can also harm normal 
cells, causing significant adverse effects. Consequently, cancer patients are increasingly 
seeking out for alternative and complementary medicins such as herbs and medicinal 
plants (Gomez et al., 2016).  
 
          Breast cancer is a disease which has diverse etiologies classified by histological, 
molecular and phenotypes. Estrogen receptor-positive (ER+) breast cancer is the most 
frequent reported breast cancer subtypes which depend on the estrogen to support the 
growth and scattered off the cancer cells (Hon et al., 2016). Tamoxifen and aromatase 
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inhibitors, are examples of the most effective endocrine therapies, to help delay or prevent 
the growth of ER+ breast cancer by blocking the actions of estrogen. However, resistance 
to these agents has become a crucial clinical challenge in the management of ER+ breast 
cancer. The MCF-7/TAMR-1 breast cancer cell line provides a model cell system for 
studying tamoxifen resistance (Viedma-RodriGuez et al., 2014).  
 
          Medicinal plants have been widely used and explored for their good potential as 
new anticancer agents. Moreover, these plants may exhibit a lesser or minimal level of 
adverse effects on healthy cells when compared with synthetic drugs (Roy et al., 2017). 
Species of genus Garcinia could affect the development and progression of breast cancer. 
Specifically, Garcinia species has been demonstrated to attenuate breast cancer 
progression through its anti-proliferative, anti-metastasic of breast tumour cells, induction 
of apoptosis and synergistic activity with chemotherapeutic drugs (Li et al., 2017).  
Garcinia hombroniana (GH), known as “seashore mangosteen” in Malaysia, is commonly 
used in traditional Malay medicine to treat different disorders such as abdominal pain and 
gonorrhoea, however little is known about its toxicological properties (Dyary et al., 2016). 
Therefore, the use of GH could be a practical attempt as a potential agent in preventing 
and treating breast cancer.  
1.2 Problem statement  
          Breast cancer is the most common malignancy in women around the world. 
Globally, it is estimated that the ratio of breast cancer is that might occur among women 
one in four (Bray et al., 2018). Tamoxifen, which is a selective ER regulator, has 
contributed to the decline in mortality rate among patients with hormone receptor-positive 
3 
 
breast cancer. However, development of resistance to tamoxifen has led to disease 
progression and death (Fagan et al., 2017). Medicinal plants have been regarded as one of 
the valuable sources of bioactive agents that may contribute to the anticancer activity. This 
includes Garcinia species, which also produces essential oils. The essential oil can be 
extracted from different parts of the plant including leaves by various methods. These 
essential oils contain a mixture of mostly volatile and triterpenoids constituents such as α-
copaene, germacrene D and β-caryophllene (Jamila et al., 2015; Tan et al., 2018). 
Furthermore, essential oils extracted from Garcinia atroviridis have been demonstrated 
to induce cytotoxicity against MCF-7 human breast cancer line (Tan et al., 2018). 
Therefore, for this study, GH leaf extract was chosen to study its anti-proliferative effect 
on breast cancer cell lines. Two models of breast cancer cell lines were used in this study, 
namely MCF-7 and MCF-7/TAMR-1. Besides that, the dose-response effects and the IC50 
values of essential oils extracted from leaves of GH were determined and established by 
using MTT assay. Furthermore, the mode of cell death via apoptosis and/or necrosis was 
determined by using Annexin-V FITC and propidium iodide staining assay by flow 
cytometry. The hypothesis of this study was GH essential oils leaves  (GH-EOL) may 
exhibit anti-proliferative effect against both cell lines through the induction of apoptosis.  
1.3 Research objectives  
          For this study, the main objective was to investigate the anti-proliferative effect of 
GH-EOL in human breast cancer cells. To achieve this, sub-objectives were constructed 
and listed as below:  
1. to extract essential oils from GH leaves by using hydrodistillation technique. 
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2. to determine the dose-response effects and to establish the IC₅₀ values of GH-EOL 
on  MCF-7 and MCF-7/TAMR-1 human breast cancer cell lines by using MTT 
assay. 
3. to determine the apoptotic or necrotic effects of GH-EOL in MCF-7 and MCF-
7/TAMR-1 human breast cancer cell lines by flow cytometry. 
1.4 Research question  
          In general this study need to investigate the anti-proliferative effect of GH-EOL in 
human breast cancer cells. Following questions had been developed: Is there an anti-
proliferative effect of GH-EOL in tamoxifen resistant human breast cancer cell line (MCF-




   
CHAPTER 2 
LITERATURE REVIEW  
2.1 Cancer  
          According to the World Health Organization (2018), cancer is defined as a complex 
disease involving abnormal cells grow uncontrollably and, in some cases, to metastasize 
(spread) nearby tissues. Worldwide, cancer is the second dominant cause of death and 9.6 
million deaths from cancer were estimated in 2018. Globally, about 1 in 6 deaths is due to 
cancer. It is also stated that cancers of the males, lung, prostate, colorectal, stomach and 
liver are the most frequently diagnosed cancers, whereas among females are breast, 
colorectal, lung, cervix, and thyroid cancers (International Agency for Research on 
Cancer, 2018).   
 
          The most common or suspected factors increase the risk of developing cancer are 
advancing age, drinking alcohol, exposure to cancer-causing substances in the 
environment (carcinogens) such as tobacco smoking and UV radiation from sunlight, 
chronic inflammation, dietary components or nutrients, hormones such as estrogens, 
immunosuppressive drugs, infectious agents including viruses, bacteria and parasites, and 
obesity (National Cancer Institute, 2015). Cancer therapies are being continually 
developed as increasing knowledge of molecular and tumour biology. There are many 
therapeutic strategies to prevent and/or cure cancer such as surgery, radiation, 
chemotherapy, immunotherapy, targeted therapy (drug only acts on cancer cell), and 
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hormone therapy (Zugazagoitia et al., 2016). However, interest is also being shown in 
alternative treatment using natural products (Shaikh et al., 2016).   
2.2 Breast cancer 
          Breast cancer is the most commonly diagnosed cancer and also the second dominant 
cause of cancer death among women in the world. In 2018, approximately 2.1 million 
women diagnosed with breast cancer, accounting for approximately 11.6% of the cancer 
cases (Bray et al., 2018). In South-East Asia, the incidence rate of breast cancer in 
Malaysia is 18 per 100,000 populations in comparison to Singapore and Thailand which 
at 15 and 11 per 100,000 populations respectively. On the other hand, the median survival 
time for breast cancer patients diagnosed in stage Ш is 50.77 months in North-East 
Peninsular Malaysia (Nordin et al., 2018).  
2.3 Breast cancer subtypes  
          Breast cancer cells often have different types of hormonal receptors including 
estrogen (ER), progesterone (PR), and human epidermal growth factor receptor 2 (HER2). 
These receptors mediate cell growth signalling. Breast cancer is divided into four 
molecular subtypes according to these receptors (Figure 2.1). Luminal A breast cancers 
are ER+, PR+, HER2-, Luminal B breast cancers are known as triple positive, are ER+, 
PR+, HER2+, HER2 enriched breast cancers are ER-, PR-, HER2+, and Triple Negative 
(basal-like) breast cancers are ER-, PR-, HER2-. Luminal A subtype account for 70 % of 
all cases, whereas Basal-like, Luminal B, and HER2 make up 15 %, 10 %, and 5 % of all 





      
              Basal                   HER2                  Luminal B                Luminal A                           
               15 %                      5 %                       10 %                         70 % 
Figure 2.1: Molecular subtypes of breast cancer 
                                      
2.4 Breast cancer risk factors  
          Breast cancer is more commonly associated with family history, obesity, sex, 
ageing, prolonged exposure to estrogen and in postmenopausal women. The family history 
of breast cancer in a first-degree relative increased the risk for both ER-positive and ER-
negative invasive breast cancer, but the level of risk varied by age and more common for 
women older than age 50 years. Similarly, postmenopausal women who were overweight 
were at risk of ER-positive and ER-negative cancer (Kerlikowske et al., 2016). The 
number of breast cancer cases occurred in women is 100 times higher than that in men 




2.5 Treatment of breast cancer  
          There is a variety of treatment for women diagnosed with breast cancer which 
include surgery, radiation therapy, chemotherapy, hormonal therapy, and targeted 
therapies. The most appropriate treatment depends on the stage and type of breast cancer, 
characteristics of the cancer cells, menopausal status, and the patient’s state of health 
(Nounou et al., 2015). 
 
           Surgical treatment to remove breast cancer involve two basic types lumpectomy 
and mastectomy. Lumpectomy, surgically removing the tumour and a small margin of 
surrounding normal epithelial tissues, but not the entire breast. Mastectomy, surgical 
removing the all breast includes nipple and areola (American Cancer Society, 2016). 
 
           Radiation therapy is often started after lumpectomy to kill any remaining cancer 
cells in a particular area by damaging DNA via radiation (Balaji et al.,2016). 
Chemotherapy is a treatment which uses drugs to enfeeble and damage tumour cells in the 
body, including cells at the primary site of cancer and any cancer cells that break away 
and spread throughout the body parts. Chemotherapy is sometimes given before surgery 
(neoadjuvant therapy) to shrink larger tumours (Pathak et al., 2018).     
 
          Hormone therapy slows or stops the growth of hormone receptor-positive breast 
cancer cells by blocking hormones from binding to receptors on tumour cells. Tamoxifen 
is one of the most common hormone therapy medications used to block estrogen receptors 
in breast cancer cells. It is often given to decrease the size of breast tumour before surgery 
to remove it, to reduce the risk of breast cancer coming back after surgery, and to treat 
breast cancer that has already spread. Another examples of hormonal therapies used in the 
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management of metastatic hormone receptor-positive breast cancer are fulvestrant act as 
an selective estrogen receptor downregulator and Letrozol act as irreversible non-steroidal 
aromatase inhibitor in postmenopasual women diagnosed with hormone receptor-positive 
breast cancer (Drãgãnescu and Carmocan, 2017). 
 
          Targeted cancer therapies are drugs that block the action of a specific protein 
(molecular target) that allows the cancer cells to grow in a rapid or abnormal way without 
harming normal cells. Hormone replacement therapies, signal transduction inhibitors, 
modulators of gene expression, apoptosis inducers, angiogenesis inhibitors, 
immunotherapies, and toxin delivery molecules are types of targeted therapies have been 
approved for use in cancer treatment (National Cancer Institute, 2019).  
2.6 Tamoxifen resistance in breast cancer 
          Around 2 out of 3 breast cancers are hormone receptor-positive. Estrogen signalling 
plays a critical role in the proliferation of breast cancer, and therefore reducing the amount 
of estrogen or blocking its action using endocrine therapy can reduce the risk of early-
stage hormone-receptor-positive breast cancers coming back. The selective estrogen 
receptor modulator (SERM), tamoxifen, is the standard treatment options for estrogen 
receptor-positive breast cancer patients. Tamoxifen treatment of estrogen receptor (ER)-
positive breast cancer reduces the annual breast cancer death rate by 31%. However, about 
half of patients with advanced ER-positive disease immediately fail to respond to 
tamoxifen and approximately 40% will acquire the resistance during the treatment 
(Hultsch et al., 2018). Acquired resistance to hormone therapy remains a major challenge 
for women with estrogen receptor-positive metastatic breast cancers.  Multiple 
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mechanisms responsible for endocrine resistance may include deregulation of various 
components of the ER pathway itself, alterations in cell cycle and cell survival signalling 
molecules, and the activation of alternative signalling pathways that can provide tumours 
with alternative proliferative and survival stimuli (Hayes and Lewis-wambi, 2015). For 
instance, breast cancer cells resist to tamoxifen treatment by overactivation the 
phosphatidylinositol-3-kinase (PI3k)/Akt and the mammalian target of rapamycin 
(mTOR) intracellular signalling pathway through cross-talk between the estrogen receptor 
and this growth factor signalling pathway. In consequence, reducing apoptosis and 
allowing the proliferation of cancer (Won et al., 2016). Another example, tamoxifen-
resistant breast cancer cells are resistant to genotoxicity mechanism of tamoxifen (DNA 
damaging through oxidative stress) by a mutation in tumour suppressor genes BARD1 
and BRCA1 (gens to protect normal cells from conversion to cancer cells). This will lead 
to loss or reduction in gens functions and then normal cells progress to cancer cells (Zhu 
et al., 2018). Due to severe side effects and multidrug resistance, these treatment 
approaches become increasingly ineffective. However, turning to complementary 
treatment approach can be a big solution for this situation, as it is evident that compounds 
derived from the natural source have a great deal of anticancer activity (Mitra and Dash, 
2018). 
2.7  Natural products derived from the plant as an alternative treatment for 
breast cancer  
          Natural plants have been used to prevent and treatment of breast cancer. Huge 
number of natural compounds from plants are identified and showed very promising anti-
cancer properties with less toxic side effects compared to current treatments such as 
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chemotherapy. Anticancer properties of natural, synthetic or biological and chemical 
agents to reverse, suppress or prevent carcinogenic progression. Natural compounds 
reduced the aggressiveness of breast cancer through various mechanisms of action, such 
as downregulating ER-α expression and activity, inhibiting proliferation, migration, 
metastasis and angiogenesis of breast tumour cells, inducing apoptosis, cell cycle arrest 
and sensitizing breast tumour cells to radiotherapy and chemotherapy (Mitra and Dash, 
2018). 
          The plant kingdom produces naturally occurring secondary metabolites which are 
being attracted to the interest of scientific and research to investigated and designed cancer 
therapeutics from natural compounds especially from phytochemicals (Greenwell and 
Rahman, 2015). Many dietary natural products could affect the development and 
progression of breast cancer, such as mangosteen (Garcinia mangostana L.) known as 
“queen of fruits”, Pomegranate (Punica granatum L.),  Mango (Mangifera indica L.), and 
Jujube (Ziziphus jujube) were used to prevent and treatment of breast cancer in South-East 
Asia (Li et al., 2017). Substantial experimental studies on the effectiveness of Garcinia 
hombroniana extract indicated that this plant is an anti-cancer agent (Dyary et al., 2016; 













2.8 Taxonomy of Garcinia hombroniana plant 
Table 2.1: Taxonomy hierarchy of Garcinia hombroniana plant  
Kingdom                                                                              Plantae 
Phylum                                                                                Tracheophyta 
Class                                                                                    Magnoliopsida 
Order                                                                                   Malpighiales 
Family                                                                                 Clusiaceae 
Genus                                                                                  Garcinia L. 
Species                                                                                Garcinia hombroniana Pierr 
                                                                     
                                                                        Adapted from (GBIF Backbone Taxonomy) 
2.9 Garcinia hombroniana   
          Garcinia is the major genus in the family Clusiaceae with over 400 species found 
throughout the tropics of Africa and Asia and about 50 species found in the lowland and 
mountains of Peninsular Malaysia (Tan et al., 2018). The genus Garcinia is reported to 
possess pharmacological activities such as antimicrobial, anti-inflammatory, anticancer, 
hepatoprotective and anti-HIV activities. Some studies have reported anti‐cholinesterase 
activity of the plant on the nervous system disorders (Jamila et al., 2017).  Traditionally, 
numerous parts of Garcinia plant (fruits, leaves, flowers, stem and bark) have been 
utilized to treat various ailments such as abdominal pain, leucorrhoea, gonorrhoea, 
diarrhoea, dysentery, wound infection, suppuration, and chronic ulcer in Malaysia, 





                 
Figure 2.2: Garcinia hombroniana leaves    
           Adapted from (plantsystematics.org) 
 
          Garcinia hombroniana plant belongs to family Clusiaceae. It is a small or medium 
evergreen tropical tree which produces globose fruit in a bright red colour. The plant is 
native to the tropical rainforests of Southeast Asian countries such as Vietnam, Cambodia, 
Malaysia and Thailand (Chew and Lim, 2018). It is known as “Manggis hutan” (seashore 
mangosteen) in Malaysia or “Waa” in Thailand. In Malaysia, it is found in the longshore 




                        
                           
                              Figure 2.3: Garcinia hombroniana tree                                     
                                            Adapted from (toptropicals.com) 
 
          In Asian and West Africa, this plant had been used for its medicinal purpose. The 
plant roots are used to make a herbal decoction for women as an anti-infective agent after 
childbirth and the leaves are used to relieve itching. The previous studies show that twigs, 
stem bark, pericarp, and leaves Garcinia hombroniana to contain alkaloids, flavonoids, 
phenols, saponins, tannins, xanthones, benzophenones, and terpenoids. Garcinia 
hombroniana leaves aqueous extract shows little toxicity on the vital organs such as the 
liver, kidneys, heart, and spleen in laboratory animals (Dyary et al., 2016). Furthermore, 
Garcinia hombroniana leaves aqueous extract has numerous therapeutic effects such as 
anti-diabetic properties due to the à-glucosidase inhibitor agent, antioxidant and 
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lipoxygenase inhibitor activity, and potential antitrypanosomal activity (Marlin et al., 
2017; Triadisti et al., 2017; Dyary et al., 2015). In addition to that, the methanol extract 
of the twigs of Garcinia hombroniana has strong antioxidant activity on human low-
density lipoprotein (LDL) and antiplatelet aggregation activities, and antibacterial activity 
against methicillin-resistant Staphylococcus aureus and S. aureus (Saputri and Jantan, 
2012; Klaiklay et al., 2013). Naturally, bioflavonoids from the bark of Garcinia 
hombroniana display significant antioxidant and antibacterial activities, and good dual 
inhibition on both acetylcholinesterase and butyryl cholinesterase (Jamila et al., 2014; 
Jamila et al.,2015). Garcinia hombroniana bark extract was also reported to possess good 
cytotoxic effect against human breast cancer (MCF7) and human glioblastoma (DBTRG) 
cell lines which might be due to the phenolic compounds (Jamila et al., 2014; Jamila et 
al.,2017).  
2.10 Cell death  
          Cell death is a very well-organized fundamental activity that is equally complex in 
regulation as cell division and differentiation. Balance homeostasis in the body is a crucial 
factor in avoiding the growth of cancer cells. Thus, activation of the cell death mechanism 
is vital in maintaining the homeostasis of proliferative of health and normal cells (Green 
and Lambi, 2015). Cell death occurs when the cells are confronted with a process which 
is reversible at first before it becomes irreversible. Loss of plasma membrane integrity, 
cell fragmentation with its nucleus into apoptotic bodies, and engulfment its fragments by 
adjacent cells are the molecular or morphological criteria to define dead cell in vivo. Cell 
death, due to the presence of its genetic regulation, can be divided into programmed (or 
active) ones, such as apoptosis and autophagy, and not programmed (or nonactive) such 
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as necrosis (Galluzzi and Vitale, 2018). Figure 2.4 shows a summary of the classification 
of the cell death pathway.       
        
Figure 2.4: Classification of cell death pathway  
Adapted from (Danial and Hockenbery, 2018) 
 
2.11 Apoptosis  
          Apoptosis is programmed and an active form of cell death in which a highly specific 
and orderly set of biochemical changes underlie the unique morphologic changes and the 
ultimate disposition of the dying cell and its contents. It is distinguished by cell shrinkage, 
nuclear fragmentation, plasma membrane blebbing and finally by the separation of the 
cellular components into apoptotic bodies. These apoptotic bodies are removed by 
phagocytes which attracted by the “eat me” signal from the exposure of 
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phosphatidylserine on the plasma membrane. Apoptosis induction can be activated by two 
different pathways, the intrinsic and extrinsic pathways. The extrinsic pathway is 
mediated by death receptors, while the intrinsic or mitochondrial pathway is triggered by 
the release of apoptogenic proteins, such as cytochrome c, which activated caspase 
proteins that are the main effector molecules that induce this process (Hassan et al., 2014).  
2.12 Necrosis 
          Necrosis has been considered as an accidental or not programmed and passive of 
cell death, and the endpoint commonly associated with very severe toxic damage.  
Necrotic cell death is characterized by an increase in cell volume, swelling of organelles, 
plasma membrane rupture and provoking an inflammatory response. The morphological 
features associated with necrosis include cellular energy depletion, damage to membrane 
lipids, and loss of function of homeostatic ion pumps/channels. It is considered as a toxic 
process because these necrotic cells are reported to release harmful chemicals that can 
induce damage to other cells. Necrosis is caused by factors external to the cell, such as 
lytic viral infection, physical trauma, complement-mediated lysis, depletion of ATP, loss 
of ionic homeostasis, and excessive ROS/RNS (Manning and Zuzel, 2010). 
2.13 Essential oils and their bio-activities  
          The essential oil is a mixture of concentrated hydrophobic liquid containing volatile 
compounds synthesized by medicinal and aromatic plants as secondary metabolites. There 
are obtained from various parts of the plant such as flowers, fruits, leaves, twigs, and barks 
(Kumar et al., 2018). There are a variety of methods for obtaining essential oils from the 
plant. Steam distillation method was found to be one of the promising techniques for 
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extraction of essential oil from plants as reputable distiller will preserve the original 
quantities of the plant. The distillation was conducted in a Clevenger apparatus in which 
boiling, condensing and decantation were done (Rassem et al., 2016). Essential oils show 
a broad range of bioactivities, especially antimicrobial activity, and have long been 
utilized for treating various human ailments and diseases. Depending on type and 
concentration, essential oils possess antimutagenic, antiproliferative, antioxidant, and 
detoxifying capabilities acting on different routes in the cancer cell as well as cancer 
preventative potentialities. The cytotoxic activity of essential oils is mostly due to the 




     
CHAPTER 3 
METHODOLOGY 
3.1 Materials and chemicals  
3.1.1 Chemicals and reagents  
All chemicals and reagents used in this study are listed in Table 3.1                                       
 Table 3.1: List of chemicals and reagents   
Chemicals and reagents Supplier 
Dimethyl Sulphoxide (DMSO) Fisher Scientific, UK 
Roswell Park Memorial Institute medium (RPMI- 
1640) 
Gibco, USA 
Phosphate Buffered Saline (PBS) Gibco, USA 
Penicillin-Streptomycin (Pen-strep) antibiotics 
solution 
Gibco, USA  
Dulbecco's Modified Eagle Medium/Nutrient 
Mixture F-12 (DMEM/F-12), no phenol red   
Gibco, USA 
Fetal Bovine Serum (FBS) Gibco, USA  
Trypsin-EDTA  Gibco, USA  
5-diphenyltetrazolium bromide dye (MTT) Calbiochem, Germany 
Trypan blue  Gibco, USA 




Garcinia hombroniana leaves  Penang Botanical Garden 
MCF-7 cell line American Type Culture 
Collection (ATCC), Virginia, 
USA 
MCF-7/TAMR-1 cell line American Type Culture 
Collection (ATCC), Virginia, 
USA 
MCF10A cell line American Type Culture 
Collection (ATCC), Virginia, 
USA 
Annexin V FITC Roche, Germany 
Propidium Iodide (PI) dye Roche, Germany 
Tamoxifen citrate salt  Nacalai tesque, Japan 
3.1.2 Consumables  
All consumables used in this study are listed in Table 3.2  
Table 3.2: List of consumables  
Consumables Supplier 
Cryogenic vials and Cryoboxes Nalgene, USA 
Micropipette tips (10µl, 200µl, 1000µl)  Labcon, Germany 
Serological pipettes (2ml, 5ml, 10ml) Nunc, Denmark 
Centrifuge tubes (15ml, 50ml) Nest Biotechnology Co., Ltd., China 
Tissue culture flasks (25 cm², 75 cm²) Becton Dickinson, USA 
Syringes (10ml)  Terumo Corporation, Philippines 
Syringes membrane filter (0.22 µm) BD Plastipak, Spain 
96-well microtiter plates  Essen Bioscience, USA 




Coverslips Deckglaser, Germany 
Counting chamber  Becton Dickinson, USA 
3.1.3 Laboratory equipment  
All of the laboratory equipment used in this study are listed in Table 3.3  
Table 3.3: List of laboratory equipment  
Name and brand Supplier 
Airstream Class II Biological Safety 
Cabinet  
ESCO, Singapore 
Centrifuge Hettich Zentrifugen, Germany  
Incubator  ThermoScientific, USA 
Water bath Memmert, Germany 
Inverted microscope  OLYMPUS, USA 
Hemocytometer  LD-Laboroptik Ltd., UK 
Microplate reader Biotek, UK 
Flow cytometer  Becton Dickinson, USA 
Clevenger-type apparatus Custom Made 
 
3.2 Extraction of essential oils by hydrodistillation technique    
          The leaves of Garcinia hombroniana were collected at Penang Botanical Garden. 
The voucher specimen (USM 11748). The leaves of Garcinia hombroniana were washed 
with distilled water and cut into small pieces prior to hydrodistillation. The 




extracts were carefully concentrated using gentle steam of nitrogen gas at room 
temperature, yielding pale yellow oils. The essential oils isolated from the leaves were 
kept at 4 ⁰c until analysis. A stock concentration 10 000 µg/ml was prepared by dissolving 
the oils in dimethyl sulphoxide (DMSO) and kept at -20 ⁰c until use. 
3.3 Cell culture  
3.3.1 Human breast adenocarcinoma cell lines  
          Two types of adenocarcinoma cell lines were used throughout this study. MCF-7 is 
an ER-positive cell line and MCF-7/TAMR-1 is an ER-positive tamoxifen resistance cell 
line, originated from human breast adenocarcinoma with epithelial morphology. MCF-
10A is an ER-alpha negative normal breast cell line. These cells were obtained from 
American Type Culture Collection (ATCC, USA). These cells were grown in suitable 
condition and the medium was changed every 2 days. All cells handling and medium 
preparation were carried out using aseptic technique in class II safety cabinet.     
3.3.2 Reagents for cell culture work  
3.3.2.1 Medium  
          MCF-7 was cultured and maintained in RPMI-1640 growth medium (Gibco, USA). 
MCF-7/TAMR-1 and MCF-10A were cultured and maintained in  Dulbecco's Modified 




at 4 ⁰C. The reagents were thawed before used and filtered-sterilised with 0.22 µm 
disposable filter unit.      
3.3.2.2  Heat-inactivated Fetal Bovine Serum (FBS) 
          A bottle of FBS (100 ml) (Gibco, USA) was stored at -20 ⁰C. The serum was 
filtered-sterilised with 0.22 µm disposable filter units and aliquoted into sterile 50 ml tubes 
and kept at -20 ⁰C. The FBS was thawed in a water bath at 37 ⁰C prior to use.  
3.3.2.3 Phosphate-Buffered Saline (PBS)  
          Ten-time Phosphate-Buffered Saline (Gibco, USA) was filtered-sterilised with 0.22 
µm disposable filter units and aliquoted into sterile 50 ml tube with distilled added to 
produce 1x working concentration. The PBS was stored at room temperature.  
3.3.2.4 Penicillin-Streptomycin (Pen-strep) antibiotics solution    
          A bottle of ready-made containing Penicillin-Streptomycin (Pen-strep) solution 
(Gibco, USA) was filtered-sterilised with 0.22 µm disposable filter units and aliquoted 
into sterile 15 ml tubes and kept at -20 ⁰C. The antibiotic was thawed in a water bath at 37 
⁰C prior to use. 
3.3.2.5 Complete growth medium  
          A complete growth medium was used in this study to culture and maintain the cell 




10 % (v/v) FBS and 1 % (v/v) of Pen Strep. The 50 ml medium was prepared by adding 5 
ml FBS, 50 µl Pen Strep and 45 ml RPMI-1640 media. The medium for MCF-7/TAMR-
1 cell line consists of DMEM/F12 without phenol red solution supplemented with FBS, 
Bovine insulin and Tamoxifen. The 50 ml medium was prepared by adding 0.5 ml FBS, 
15 µl Bovine insulin, 5 µl Tamoxifen and 49.5 ml DMEM/F12 without phenol red media. 
The medium for MCF-10A cell line consists of DMEM/F12 with phenol red solution 
supplemented with horse serum, insulin, hEGF enzyme, hydrocortisone, and Pen Strep. 
The 50 ml medium was prepared by adding 47.5 ml DMEM/F12 with phenol red solution, 
2.5 ml horse serum, 125µl insulin, 50µl hEGF enzyme, 500µl hydrocortisone, and 50µl 
Pen Strep. All prepared media were kept at 4 ⁰C and thawed before used.   
3.3.2.6 Trypsin (0.25%, w/v)/ EDTA (0.03%, w/v) solution  
          Ready-made trypsin of 0.25%, EDTA 0.03% was filter-sterilised, aliquoted into 
sterile 15 ml tubes and stored at -20 ⁰C until use. The trypsin was thawed in 37 ⁰C prior to 
use.     
   
3.3.2.7 Cryogenic Medium  
          The cryogenic medium for MCF-7 cell line contained 95% RPMI complete medium 
and 5% DMSO. The 10 ml cryogenic medium was prepared by adding filtered-sterilised 
9.5 ml RPMI complete media and 0.5 ml DMSO. The cryogenic medium for MCF-
7/TAMR-1 and MCF-10A cell line contained 95% DMEM/F12 complete medium and 5% 




DMEM/F12 complete media and 0.5 ml DMSO. Both cryogenic mediums were prepared 
fresh and kept cold prior to use.  
 
3.3.3 Culture procedures and conditions  
          All tissue culture procedures were carried out in a sterile condition (Airstream Class 
II Biological Safety Cabinet) using aseptic techniques to avoid any contamination. Cells 
were cultured in growth medium and maintained in a humidified incubator at 37 ⁰C in an 
atmosphere in a 5 % CO2 and 95 % air.  
3.3.4 Thawing of cells from frozen storage  
          The frozen cells were retrieved from the -80 ⁰C storage and thawed in a water bath 
at 37 ⁰C for 2 minutes. The entire frozen cells were gently pipetted into a 15 ml centrifuge 
tube containing 2 ml pre-warmed complete growth medium. The content centrifuged at 
1000 rpm for 5 minutes to remove DMSO for MCF-7 cell and at 300 g for 4 minutes to 
remove DMSO for MCF-7/TAMR-1 and MCF-10A cells. The supernatant was aspirated 
and the cell pellet was then resuspended in 1-2 ml of complete growth medium. The cell 
suspension was then slowly pipetted into a 25 cm² tissue culture flask containing 4-5 ml 
culture media. The cell morphology was observed using an inverted phase-contrast 
microscope to check for cell viability. The culture flask was incubated in a humidified 
atmosphere containing 5 % CO2 at 37 ⁰C. The growth medium was replaced every 2-3 
days. 
